Amanda Horn
Family · Wellington, OHNPI 1538556626
Payments from drug & device makers
Across 77 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$239
- Otsuka America Pharmaceutical, Inc.$135
- IBSA Pharma Inc.$94
- Bayer$92
- Takeda Pharmaceuticals U.S.A., Inc.$76
- Lilly USA, LLC$75
- plus $509 from 15 others
What the payments were for
- Food & beverage$1,221100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $239 |
| Otsuka America Pharmaceutical, Inc. | 8 | $135 |
| IBSA Pharma Inc. | 7 | $94 |
| Bayer | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $76 |
| Lilly USA, LLC | 5 | $75 |
| Biohaven Pharmaceuticals, Inc. | 4 | $67 |
| Amarin Pharma, Inc. | 4 | $66 |
| Novo Nordisk | 4 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $53 |
| Boehringer Ingelheim | 3 | $42 |
| Phadia US Inc. | 2 | $37 |
| Merck | 3 | $36 |
| Dexcom, Inc. | 2 | $31 |
| Pfizer | 1 | $25 |
| Exact Sciences | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| AstraZeneca | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$1,221 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $37,225 |
| MounjaroTirzepatide | 19 | $23,660 |
| EliquisApixaban | 18 | $22,865 |
| FarxigaDapagliflozin Propanediol | 21 | $17,831 |
| TrulicityDulaglutide | 13 | $15,580 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $14,182 |
| XareltoRivaroxaban | 13 | $10,363 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $3,050 |
| Pregabalin | 13 | $2,770 |
| Dexlansoprazole DrDexlansoprazole | 12 | $2,255 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $2,249 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 44 | $1,347 |
| Vilazodone Hcl | 11 | $1,336 |
| Atorvastatin Calcium | 135 | $1,304 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $75 | $39,24132 claims |
| Novo NordiskOzempic | $64 | $37,22531 claims |
| PfizerEliquis | $25 | $22,86518 claims |
| AstraZenecaFarxiga | $14 | $17,83121 claims |
| AbbVieSynthroid | $239 | $1,04226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.
Other family in Wellington
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.